Summary:
- Acclaro Medical, a medical technology company in Smithfield, RI, secured $23M in Series B funding led by Accelmed Partners.
- The funding will be used to grow their flagship products, UltraClear and AuraLux, and expand globally while developing new products.
- Acclaro Medical, led by CEO Helen Fang, focuses on innovative solutions for medical, aesthetic, and surgical needs, offering painless anti-aging treatments with their UltraClear laser platform.
—
Acclaro Medical, a leading medical technology company based in Smithfield, Rhode Island, recently announced a significant milestone in its growth journey. The company successfully closed a Series B funding round, raising an impressive $23 million. This funding round was spearheaded by Accelmed Partners, a prominent investor in the healthcare industry, with participation from existing investor 3E Bioventures Capital.
The primary objective of this funding injection is to accelerate the growth and expansion of Acclaro Medical’s flagship products, UltraClear and AuraLux. These cutting-edge solutions have already made a significant impact in the market, offering innovative approaches to patient care and medical practices. Additionally, the funds will be instrumental in driving the company’s global market expansion strategy while also fueling the development of new products in their pipeline.
At the helm of Acclaro Medical is CEO Helen Fang, a visionary leader dedicated to addressing unmet medical, aesthetic, and surgical needs through innovative solutions. One of the standout products from Acclaro Medical is UltraClear, a cold, ablative fiber laser platform that revolutionizes anti-aging treatments. What sets UltraClear apart is its painless nature, eliminating the need for topical numbing in most procedures. Powered by advanced technologies like 3DMIRACL and 3DIntelliPulse, UltraClear offers a diverse range of skin rejuvenation outcomes, from anti-aging treatments with zero downtime to advanced collagen remodeling procedures.
In conclusion, Acclaro Medical’s successful Series B funding round marks a significant milestone in the company’s growth trajectory. With a strong focus on innovation and addressing unmet medical needs, Acclaro Medical is well-positioned to continue making a positive impact in the healthcare industry. The funding infusion will not only drive the growth of their existing products but also pave the way for the development of groundbreaking solutions that will shape the future of patient care and medical practices.
